高级检索
当前位置: 首页 > 详情页

Effects of resveratrol in an animal model of osteoporosis: a meta-analysis of preclinical evidence

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China [2]Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China [3]Res Team Bone & Joint Degenerat & Injury Guangdong, Guangzhou, Peoples R China [4]Guangzhou Univ Chinese Med, Clin Coll 5, Guangzhou, Peoples R China [5]Guangdong Prov Enginering Technol Res Inst Tradit, Guangdong Second Chinese Med Hosp, Guangzhou, Peoples R China
出处:
ISSN:

关键词: resveratrol plant-based natural products osteoporosis bone mineral density meta-analysis evidence-based medicine

摘要:
Background: Resveratrol is a natural polyphenol compound that is widely present in herbal medicines such as Reynoutria japonica Houtt., Veratrum nigrum L., and Catsiatora Linn and is used in traditional Chinese medicine to treat metabolic bone deseases. Animal experiments have shown that resveratrol may have a strong treatment effect against osteoporosis (OP). The purpose of this study was to explore the efficacy of resveratrol in treating OP animal models based on preclinical research data.Methods: This study was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases from inception to May 8, 2023, to identify animal experiments on the treatment of OP with resveratrol. The effect sizes of bone mineral density (BMD), parameters of micro-CT, serum calcium, phosphorus, alkaline phosphatase (ALP) and osteocalcin were expressed as the mean differences (MDs) and 95% confidence intervals (CIs). RevMan 5.4 software was used for data analysis.Results: This meta-analysis included a total of 15 animal experiments, including 438 OP rats. The meta-analysis results showed that compared with the control group, resveratrol (<10, 10-25, 40-50, =60 mg/kg/day) significantly increased femoral and lumbar bone mineral density (BMD) in OP rats (p < 0.05). Resveratrol (<10 mg/kg/day) significantly increased the BMD of the total body (MD = 0.01, 95% CI: 0.01 to 0.01, p < 0.001). In terms of improving the parameters related to micro-CT, resveratrol (40-50 mg/kg/day) can increase trabecular thickness and trabecular number and reduce trabecular spacing (p < 0.05). Compared with the control group, resveratrol can reduce the concentration of calcium and phosphorus in serum but has no significant effect on serum ALP and osteocalcin (p > 0.05). The results of subgroup analysis showed that resveratrol increased the whole-body BMD of SD rats (p = 0.002) but did not improve the whole-body BMD of 3-month-old rats (p = 0.17).Conclusion: Resveratrol can increase BMD in OP rat models, and its mechanism of action may be related to improving bone microstructure and regulating calcium and phosphorus metabolism. The clinical efficacy of resveratrol in the treatment of OP deserves further research.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 农林科学
小类 | 2 区 营养学
最新[2025]版:
大类 | 2 区 农林科学
小类 | 3 区 营养学
JCR分区:
出版当年[2021]版:
Q1 NUTRITION & DIETETICS
最新[2023]版:
Q2 NUTRITION & DIETETICS

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China [2]Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China [3]Res Team Bone & Joint Degenerat & Injury Guangdong, Guangzhou, Peoples R China
通讯作者:
通讯机构: [1]Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China [2]Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China [3]Res Team Bone & Joint Degenerat & Injury Guangdong, Guangzhou, Peoples R China [4]Guangzhou Univ Chinese Med, Clin Coll 5, Guangzhou, Peoples R China [5]Guangdong Prov Enginering Technol Res Inst Tradit, Guangdong Second Chinese Med Hosp, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号